Bank living tumor organoids at resection. If your patient ever relapses, we'll find what works next.
70% of cancer patients eventually fail first-line therapy. When that happens, their oncologist is left guessing — trying drug after drug, hoping something works.
By then, the original tumor tissue is long gone. Getting a new biopsy at relapse is invasive, often difficult, and sometimes impossible.
You hold the answer in your hands — at the time of surgery.
A small tissue sample that would otherwise be discarded can become a living replica of your patient's cancer, banked indefinitely, ready to guide treatment if they ever need it.
What makes this different: Unlike frozen tissue or genomic sequencing, patient-derived organoids are living, functional models that can be tested against thousands of drugs to predict what will actually work for each individual patient.
A simple workflow that fits seamlessly into your existing OR routine
At resection, place a small tumor sample (pea-sized) in our transport media. Takes 5 minutes, no extra OR time required. We provide all collection supplies.
We grow patient-derived organoids from the tissue and cryopreserve them at no cost to you or your patient. The organoids can be stored indefinitely.
If your patient relapses, we thaw their organoids and screen them against 1,800+ FDA-approved drugs to identify what therapies are most likely to work.
Their oncologist receives a clinician-ready report showing which therapies are most likely to work — delivered in under 21 days from testing initiation.
Functional testing shows what actually works, not just what might work based on genomics alone
Banking is free; patients only pay if and when they need testing at relapse
Published clinical studies demonstrate strong correlation between organoid response and patient outcomes
Every sample we bank contributes to the largest drug-response dataset in precision oncology.
We're building AI models that will predict effective therapies without physical testing — faster, cheaper, and at scale.
Your patients benefit today. Future patients benefit from the data.
We handle everything else — shipping, culture, banking, and storage.
We're currently partnering with surgical oncology teams to bank samples for:
Other solid tumors may be eligible — contact us to discuss.
We're partnering with select surgical oncology teams across Canada to bank samples for ovarian, pancreatic, colorectal, and triple-negative breast cancer patients.
Interested in offering this to your patients? Fill out the form below or contact us directly.
We provide collection kits, consent forms, and shipping supplies
Pilot program with free banking for initial patients
Scientific liaison available for questions and case consultation
Interested in offering organoid banking to your surgical patients? Fill out the form below and we'll be in touch within 24 hours.
No. Sample collection takes about 5 minutes and can be done while the patient is being closed. It requires no additional OR time or specialized equipment.
A pea-sized sample (approximately 5mm³) of viable tumor tissue is sufficient. This is tissue that would typically be discarded after pathology review.
We provide transport media and shipping containers. Samples are shipped overnight at 4°C using standard courier services. We handle all logistics.
Our success rate exceeds 85% for suitable tissue samples. If culture fails, there is no cost to the patient. We communicate all results to you and the patient's care team.
Banking and storage are provided at no cost. Patients only pay if and when they need drug sensitivity testing at relapse. There is no financial burden unless the service is actually used.
We provide patient education materials and consent forms. Most patients understand the concept quickly: "We're saving a living sample of your tumor in case you ever need it to guide future treatment."